Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?

Arthritis Research and Therapy

Volumn 7, Issue 2, 2005, Pages 55-61

  McCarey, David W ^a   Sattar, Naveed ^a   McInnes, Iain B ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CERIVASTATIN; CHEMOKINE; CHOLESTEROL; COLLAGEN; CYCLOOXYGENASE 2; CYTOKINE; FLUINDOSTATIN; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVALONIC ACID; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTHRITIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CLINICAL TRIAL; CYTOKINE RELEASE; DATA ANALYSIS; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ENDOTHELIUM CELL; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; LEUKOCYTE FUNCTION; LIVER TOXICITY; MONOCYTE; NONHUMAN; PLEIOTROPY; POLYMORPHONUCLEAR CELL; PREDICTION; PROTECTION; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; RHEUMATOID ARTHRITIS; UPREGULATION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICHOLESTEREMIC AGENTS; APOPTOSIS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CELL ADHESION MOLECULES; CHEMOKINES; CLINICAL TRIALS; CYTOKINES; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; EDEMA; ENDOTHELIUM, VASCULAR; GRAFT REJECTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; INFLAMMATION; KIDNEY TRANSPLANTATION; MICE; MOLECULAR STRUCTURE; MONOCYTES; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RATS;

EID: 15944397265     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1496     Document Type: Review

References (54)

1. Hamelin BA, Turgeon J: Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998, 19:26-37.
2. Furberg CD, Pitt B: Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001, 2: 05-207.
3. Ishigami M, Honda T, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y: A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos 2001, 29:282-288.
4. Olsson AG, Pears J, McKellar J, Mizan J, Raza A: Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001, 88:504-508.
5. Farnier M, Davignon J: Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 1998, 82: J-10J.
6. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, et al.: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996, 275:128-133.
7. Blum CB: Comparison of properties of four inhibitors of 3-hydroxy-3- methylglutaryl-coenzyme A reductase. Am J Cardiol 1994, 73:3D-11D.
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
9. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
10. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
11. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
12. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
13. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A: Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001, 77:247-253.
14. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004, 350:1387-1397.
15. Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammmation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286:64-70.
16. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS: Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002, 87:563-568.
17. Seljeflot I, Tonstad S, Hjermann I, Arnesen H: Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 2002, 162:179-185.
18. Li D, Chen H, Romeo F, Sawamura T, Saldeen T, Mehta JL: Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Pharmacol Exp Ther 2002, 302:601-605.
19. Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, Wada Y, Izumi A, Saito Y, Hamakubo T, Kodama T: The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. J Atheroscler Thromb 2002, 9: 78-183.
20. Wagner AH, Gebauer M, Guldenzoph B, Hecker M: 3-Hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol 2002, 22:1784-1789.
21. Seljeflot I, Tonstad S, Hjermann I, Arnesen H: Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res 2002, 105: 85-290.
22. Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G: Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 2000, 152:359-366.
23. Bourcier T, Libby P: HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000, 20:556-562.
24. Wiesbauer F, Kaun C, Zorn G, Maurer G, Huber K, Wojta J: HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 2002, 135:284-292.
25. Fenton JW 2nd, Jeske WP, Catalfamo JL, Brezniak DV, Moon DG, Shen GX: Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Biochemistry (Mosc) 2002, 67: 5-91.
26. Mason JC, Ahmed Z, Mankoff R, Lidington EA, Ahmad S, Bhatia V, Kinderlerer A, Randi AM, Haskard DO: Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res 2002, 91: 696-703.
27. Matsumoto I, Maccioni M, Lee DM, Maurice M, Simmons B, Brenner M, Mathis D, Benoist C: How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol 2002 Apr;3:360-365.
28. Yilmaz A, Reiss C, Tantawi O, Weng A, Stumpf C, Raaz D, Ludwig J, Berger T, Steinkasserer A, Daniel WG, et al.: HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 2004, 172: 5-93.
29. Grip O, Janciauskiene S, Lindgren S: Atorvastatin activates PPAR-γ and attenuates the inflammatory response in human monocytes. Inflamm Res 2002, 51:58-62.
30. Hilgendorff A, Muth H, Parviz B, Staubitz A, Haberbosch W, Tillmanns H, Holschermann H: Statins differ in their ability to block NF-κB activation in human blood monocytes. Int J Clin Pharmacol Ther 2003, 41:397-401.
31. Hernandez-Presa MA, Martin-Ventura JL, Ortego M, Gomez-Hernandez A, Tunon J, Hernandez-Vargas P, Blanco-Colio LM, Mas S, Aparicio C, Ortega L, et al.: Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 2002, 160:49-58.
32. Xu ZM, Zhao SP, Li QZ, Nie S, Zhou HN: Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta 2003, 338:17-24.
33. Ruiz-Velasco N, Dominguez A, Vega MA: Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-γ ligands. Putative contribution of Rho GTPases in statin-induced CD36 expression. Biochem Pharmacol 2004, 67: 03-313.
34. Choi M, Rolle S, Rane M, Haller H, Luft FC, Kettritz R: Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int 2003, 63:96-106.
35. de F, Sanchez de Miguel L, Farre J, Gomez J, Romero J, Marcos-Alberca P, Nunez A, Rico L, Lopez-Farre A: Expression of an endothelial-type nitric oxide synthase isoform in human neutrophils: modification by tumor necrosis factor-alpha and during acute myocardial infarction. J Am Coll Cardiol 2001, 37: 800-807.
36. McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY: A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004, 172:2903-2908.
37. Kwak B, Mulhaupt F, Myit S, Mach F: Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6: 399-1402.
38. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001, 7:687-692.
39. McInnes IB, Leung BP, Liew FY: Cell-cell interactions in synovitis. Interactions between T lymphocytes and synovial cells. Arthritis Res 2000, 2:374-378.
40. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, et al.: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84.
41. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, Numabe A, Saito K, Negoro H, Fujita T, Toyo-oka T, Kato T: Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003, 93: 948-956.
42. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbell C, Gracie JA, Liew FY, et al.: A novel antiinflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003, 170:1524-1530.
43. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, et al.: Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001, 21:115-121.
44. Palmer G, Chobaz V, Talabat D, Taylor S, So A, Gabay C, Busso N: Statins have no effect on collagen-induced arthritis in mice. Arthritis Res Ther 2004, Suppl 1:100.
45. Pahan K, Sheikh FG, Namboodiri AM, Singh I: Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997, 100:2671-2679.
46. Kumagai K, Nakashima H, Saku K: The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004, 62:105-111.
47. Yokota N, O'Donnell M, Daniels F, Burne-Taney M, Keane W, Kasiske B, Rabb H: Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Am J Nephrol 2003, 23:13-17.
48. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M, Cohen AH, Teraski PI, et al.: The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996, 61:1469-1474.
49. Holdaas H, Jardine AG, Wheeler DC, Brekke IB, Conlon PJ, Fellstrom B, Hammad A, Holme I, Isoniemi H, Moore R, et al.: Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int 2001, 60:1990-1997.
50. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, Seidel D, Reichart B: Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997, 96:1398-1402.
51. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621-627.
52. Pasceri V, Yeh ET: A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999, 100:2124-2126.
53. Pincus T, Sokka T, Wolfe F: Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum 2001, 44:1234-1236.
54. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N: Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004, 363:2015-2021.